CELEBRATING 120 YEARS: ONE OF THE WORLD’S LARGEST SITES DEDICATED TO THE RESEARCH, DEVELOPMENT AND PRODUCTION OF VACCINES CAMPUS SERVES AS THE U.S. HEADQUARTERS FOR SANOFI PASTEUR
A HISTORIC CAMPUS CELEBRATES 120 YEARS OF VACCINE EXPERTISE
• The Swiftwater site was founded in 1897 by Dr. Richard Slee as the Pocono Biological Laboratories.
• The laboratories later became part of the National Drug Company, then Connaught Laboratories, followed by Pasteur Mérieux Connaught, and Aventis Pasteur.
• Established on four acres nestled in the scenic Pocono Mountains of Pennsylvania, the site has an impressive 120 years of vaccine experience.
• The now 500-plus acre campus has more than 50 buildings and is a global center of scientific and industrial expertise.
• Swiftwater has a dedicated workforce of more than 2,500 people in Industrial Operations, R&D, Commercial Operations, and various Support Functions.
WORLD’S LEADING SEASONAL INFLUENZA VACCINE MANUFACTURER
• The Swiftwater site, today owned by Sanofi Pasteur and formerly the Pocono Biological Laboratories founded in 1897, licensed its first influenza vaccine in 1947.
• After doubling its global vaccine production capacity in the past 10 years, Sanofi Pasteur now produces more than 200 million doses of seasonal influenza vaccine for worldwide distribution.
• Sanofi Pasteur provides approximately 40% of the global influenza vaccine supply and at least 60 million doses for the United States.
• Sanofi Pasteur continues to discover and deliver a variety of influenza vaccine improvements. Our innovations include:
o The first high-dose influenza vaccine for adults aged 65 and over,
COM 11626-1R Swiftwater Fact Sheet June 2017 o Quadrivalent influenza vaccines to help provide broad protection against influenza by containing two A strains and two B strains,
o The first pediatric influenza vaccine for children as young as six months of age.
• Sanofi Pasteur is actively exploring several leading influenza vaccine developments, ranging from broadly protective to universal flu vaccines, through both internal and external collaborations.
• Sanofi Pasteur’s Swiftwater campus is designed and built to standards that allow Sanofi Pasteur to switch from production of seasonal influenza vaccine to pandemic influenza vaccine.
PROVIDING VACCINES TO MEET GROWING GLOBAL PUBLIC HEALTH NEEDS
• Sanofi Pasteur has played a critical role in responding to the changing needs of public health by developing innovative products such as combination pediatric vaccines, meningococcal meningitis vaccines, and novel influenza vaccines.
• The Swiftwater site produces, fills, formulates, inspects and/or packages vaccines for seven diseases: influenza, pertussis, diphtheria, meningococcal disease, Haemophilus influenzae type b (Hib) infections, tetanus, and yellow fever.
• In addition to its licensed products, Sanofi Pasteur is investing in a number of Research and Development projects, including vaccine candidates, to help prevent dengue fever and symptomatic Clostridium difficile infection.
SITE GROWTH CONTINUES WITH INVESTMENTS IN EXCESS OF $1.3 BILLION
• Since 2000, the Swiftwater site has made a number of investments to support the changing needs of public health. The more recent projects include:
o Construction of a new Formulation, Filling and Lyophilization facility to provide yellow fever vaccine and the dengue fever vaccine1 began in 2014 with FDA licensure anticipated in 2018.
o Construction began in 2015 of a Quality Control facility to provide testing capabilities for all products manufac- tured on site and became operational in 2016 ahead of schedule.
o Construction for the new Global Clinical Immunology facility featuring bio-safety level laboratory space broke ground in 2015 and will support the development of the company’s new vaccines portfolio.
CONTACT: US Media Relations T. (570) 957-0717 [email protected] www.sanofipasteur.us
1 As of June of 2017, the dengue fever vaccine candidate has been licensed in Mexico, the Philippines and a dozen other endemic countries.
COM 11626-1R Swiftwater Fact Sheet June 2017